Item 8.01. Other Events.



On April 11, 2021, BeiGene, Ltd. (the "Company") announced that clinical data on
its anti-PD-1 antibody tislelizumab, in combination with the investigational
spectrum-selective kinase inhibitor sitravatinib being jointly developed with
Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at
the American Association for Cancer Research (AACR) Annual Meeting 2021. Data
presented at the meeting were from two cohorts of a Phase 1b trial
(NCT03666143), in patients with unresectable or metastatic melanoma who were
refractory or resistant to PD-1/L1 inhibitors and in patients with advanced
platinum-resistant ovarian cancer (PROC). The full text of this press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

On April 12, 2021, the Company announced results from a planned interim analysis
of the Phase 3 RATIONALE 303 trial of its anti-PD-1 antibody tislelizumab
compared to docetaxel as second- or third-line therapy for patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) in an oral
presentation at the AACR Annual Meeting 2021. A supplemental biologics
application (sBLA) based on these results from the RATIONALE 303 trial was
accepted in March 2021 and is currently under regulatory review in China. The
full text of this press release is filed as Exhibit 99.2 to this Current Report
on Form 8-K and is incorporated herein by reference.

9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.           Description

       99.1              Press Release titled "BeiGene Presents Clinical Data on Sitravatinib in
                         Combination with Tislelizumab at the AACR Annual Meeting 2021" issued on
                         April 11, 2021.

       99.2              Press Release titled "BeiGene Presents Interim Analysis Results of
                         RATIONALE 303 Trial of Tislelizumab in Second- or

Third-Line Non-Small Cell

Lung Cancer at the AACR Annual Meeting 2021"

issued on April 12, 2021.


       104               The cover page from this Current Report on Form

8-K, formatted in Inline


                         XBRL.





--------------------------------------------------------------------------------



                                 Exhibit Index

   Exhibit No.           Description

       99.1                Press Release     title    d     "    B

eiGene Presents Clinical Data on


                         Sitravatinib in Combination with Tislelizumab at

the AACR Annual Meeting


                         2021    "     issued     on April     11    ,

2021.


       99.2                Press Release     titled "    BeiGene Presents

Interim Analysis Results of


                         RATIONALE 303 Trial of Tislelizumab in Second- or

Third-Line Non-Small Cell

Lung Cancer at the AACR Annual Meeting 2021    "

issued on April 12, 2021.


       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses